IMMP vs. ARQT, OPK, LQDA, INVA, VRNA, IRWD, BCYC, OCUL, GYRE, and IMNM
Should you be buying Immutep stock or one of its competitors? The main competitors of Immutep include Arcutis Biotherapeutics (ARQT), OPKO Health (OPK), Liquidia (LQDA), Innoviva (INVA), Verona Pharma (VRNA), Ironwood Pharmaceuticals (IRWD), Bicycle Therapeutics (BCYC), Ocular Therapeutix (OCUL), Gyre Therapeutics (GYRE), and Immunome (IMNM). These companies are all part of the "pharmaceutical preparations" industry.
Immutep (NASDAQ:IMMP) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, community ranking, valuation, risk, institutional ownership and earnings.
Immutep currently has a consensus target price of $8.50, suggesting a potential upside of 185.23%. Arcutis Biotherapeutics has a consensus target price of $25.38, suggesting a potential upside of 203.53%. Given Arcutis Biotherapeutics' higher probable upside, analysts clearly believe Arcutis Biotherapeutics is more favorable than Immutep.
Immutep has higher earnings, but lower revenue than Arcutis Biotherapeutics.
In the previous week, Arcutis Biotherapeutics had 6 more articles in the media than Immutep. MarketBeat recorded 10 mentions for Arcutis Biotherapeutics and 4 mentions for Immutep. Immutep's average media sentiment score of 0.86 beat Arcutis Biotherapeutics' score of 0.67 indicating that Immutep is being referred to more favorably in the media.
Immutep has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -204.35%. Immutep's return on equity of 0.00% beat Arcutis Biotherapeutics' return on equity.
Immutep received 256 more outperform votes than Arcutis Biotherapeutics when rated by MarketBeat users. Likewise, 72.43% of users gave Immutep an outperform vote while only 62.07% of users gave Arcutis Biotherapeutics an outperform vote.
Immutep has a beta of 2.1, meaning that its stock price is 110% more volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500.
2.3% of Immutep shares are held by institutional investors. 3.1% of Immutep shares are held by insiders. Comparatively, 9.5% of Arcutis Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Immutep beats Arcutis Biotherapeutics on 11 of the 16 factors compared between the two stocks.
Get Immutep News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
